International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Amgen Announced the United States Food and Drug Administration (FDA) Approval of AMJEVITA™

Psoriasis News Amgen Blog Graphic

Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.

Categories

Recent Posts

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Improving Medical Adherence in Psoriasis Treatments

Shining a Spotlight: Catching up with 2018 IPC Fellow Filip Rob, MD, PhD

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.